Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study

Progress in Neuro-psychopharmacology & Biological Psychiatry
José Manuel MontesEFESO Study Group

Abstract

This study evaluated the effectiveness, safety, and quality of life (Qol) offered by olanzapine in first-episode schizophrenia. One hundred and eighty-two patients with first-episode schizophrenia (ICD-10) drawn from a larger, naturalistic, study were evaluated after 6 months of treatment with olanzapine, risperidone, or conventional antipsychotics (CA). Clinical status was assessed using the Clinical Global Impression-Severity (CGI-S) and Global Assessment of Function (GAF). AWAD and EuroQol scales were used to evaluate patients' attitude towards medication and Qol, respectively. Subjects treated with olanzapine, risperidone, and CA showed similar improvements on CGI-S and GAF. Treatment-emergent, extrapyramidal symptoms were significantly lower in olanzapine-treated patients (17.8%) than in the risperidone (46.4%) and CA (62.2%) groups. Compared to CA, olanzapine and risperidone showed significantly greater improvement on the visual analog scale of EuroQol. Olanzapine-treated patients also showed significantly improved AWAD scores. In first-episode schizophrenia, atypical antipsychotics were effective, and improved Qol. Olanzapine had a lower incidence of extrapyramidal symptoms and better subjective acceptance of medication.

References

Jan 1, 1992·Schizophrenia Bulletin·R RamJ E Schwartz
Jan 1, 1995·The British Journal of Psychiatry : the Journal of Mental Science·H G HwuL L Yeh
Jan 1, 1994·Acta Psychiatrica Scandinavica. Supplementum·A G Awad, T P Hogan
Feb 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·C M BeasleyS Hamilton
Mar 1, 1996·Psychopharmacology·C M BeasleyS Hamilton
Apr 1, 1996·The Netherlands Journal of Medicine·B Blackwell
May 1, 1997·The British Journal of Psychiatry : the Journal of Mental Science·M FranzB Gallhofer
Dec 31, 1997·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·S H HamiltonC M Beasley
Sep 24, 1999·Acta Psychiatrica Scandinavica·O Kampman, K Lehtinen

❮ Previous
Next ❯

Citations

Aug 10, 2006·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Stephen M BeardEckart Rüther
Sep 15, 2004·European Psychiatry : the Journal of the Association of European Psychiatrists·Antonio CiudadUNKNOWN EFESO Study Group
May 14, 2005·Psychiatry Research·Michael RitsnerAnatoly Gibel
Jun 1, 2013·Gaceta sanitaria·Lidia García-PérezAmado Rivero-Santana
Dec 1, 2010·Asian Journal of Psychiatry·Pudtan PhanthunaneMelanie Bertram
Jul 4, 2008·L'Encéphale·J-Y RotgéJ Tignol
Feb 10, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Peter M WehmeierWolfgang Schreiber
Nov 1, 2008·Early Intervention in Psychiatry·Salvatore De MasiGiovanni De Girolamo
Mar 19, 2009·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Jun Soo Kwon, Jung-Seok Choi
Dec 2, 2004·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Ruth I OhlsenLyn S Pilowsky
Jan 18, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·S Nassir GhaemiFrederick K Goodwin
Jan 1, 2005·International Journal of Psychiatry in Clinical Practice·Martin LambertBenno Graf Schimmelmann
Oct 4, 2008·Journal of Psychiatric Practice·Brian J Miller
Jul 18, 2008·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Jason H KarlawishHenry A Glick
Dec 5, 2006·European Psychiatry : the Journal of the Association of European Psychiatrists·Hans-Helmut KönigMatthias C Angermeyer
Feb 20, 2004·Pharmacoepidemiology and Drug Safety
Jan 1, 2007·International Journal of Psychiatry in Clinical Practice·Juan Gibert For The Sos Group 1
Aug 2, 2005·The British Journal of Psychiatry : the Journal of Mental Science·Sylvia ParkStephen B Soumerai

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.